FRAMINGHAM, MA--(MARKET WIRE)--Aug 17, 2007 -- Symbollon Pharmaceuticals, Inc. (OTC BB:SYMBA.OB - News) today announced financial results for the second quarter ended June 30, 2007. For the three months ended June 30, 2007, the Company reported a net loss of $1,131,254, or $0.09 per share, compared with a net loss of $645,770, or $0.08 per share, in the prior year. For the six months ended June 30, 2007, the Company reported a net loss of $2,470,624, or $0.20 per share, compared with a net loss of $1,194,541, or $0.15 per share, in the prior year. The increased loss for such periods resulted primarily from increased clinical development expenses related to the ongoing clinical trials of IoGen(TM) and consulting and other service expenses.
